Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to 173.51%.

  • ImmunityBio's EBITDA Margin rose 11408200.0% to 173.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 315.84%, marking a year-over-year increase of 45964700.0%. This contributed to the annual value of 2334.23% for FY2024, which is 559053200.0% up from last year.
  • Latest data reveals that ImmunityBio reported EBITDA Margin of 173.51% as of Q3 2025, which was up 11408200.0% from 269.76% recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's EBITDA Margin ranged from a high of 173.51% in Q3 2025 and a low of 685514.29% during Q1 2022
  • Over the past 5 years, ImmunityBio's median EBITDA Margin value was 61430.94% (recorded in 2023), while the average stood at 104305.43%.
  • In the last 5 years, ImmunityBio's EBITDA Margin plummeted by 2000000000bps in 2022 and then soared by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows ImmunityBio's EBITDA Margin stood at 20326.67% in 2021, then crashed by -472bps to 116301.37% in 2022, then surged by 47bps to 61430.94% in 2023, then skyrocketed by 99bps to 918.96% in 2024, then soared by 81bps to 173.51% in 2025.
  • Its EBITDA Margin was 173.51% in Q3 2025, compared to 269.76% in Q2 2025 and 390.08% in Q1 2025.